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A defined mechanistic correlate of protection
against Plasmodium falciparum malaria
in non-human primates
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Gavin J. Wright4, Carole A. Long3, Joseph M. Royal2 & Simon J. Draper 1
Malaria vaccine design and prioritization has been hindered by the lack of a mechanistic
correlate of protection. We previously demonstrated a strong association between protection
and merozoite-neutralizing antibody responses following vaccination of non-human primates
against Plasmodium falciparum reticulocyte binding protein homolog 5 (PfRH5). Here, we test
the mechanism of protection. Using mutant human IgG1 Fc regions engineered not to engage
complement or FcR-dependent effector mechanisms, we produce merozoite-neutralizing and
non-neutralizing anti-PfRH5 chimeric monoclonal antibodies (mAbs) and perform a passive
transfer-P. falciparum challenge study in Aotus nancymaae monkeys. At the highest dose
tested, 6/6 animals given the neutralizing PfRH5-binding mAb c2AC7 survive the challenge
without treatment, compared to 0/6 animals given non-neutralizing PfRH5-binding mAb
c4BA7 and 0/6 animals given an isotype control mAb. Our results address the controversy
regarding whether merozoite-neutralizing antibody can cause protection against P. falciparum
blood-stage infections, and highlight the quantitative challenge of achieving such protection.
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o our knowledge, immunological protection against the
disease-causing blood-stage of the major human malaria
parasite Plasmodium falciparum has never been proven to
be caused by any single specific immunological mechanism.
Numerous immune effectors have been proposed as potential
mediators of both naturally acquired and vaccine-induced pro-
tection against the P. falciparum blood-stage: merozoite neu-
tralization independent of FcR bearing cells (either with or
without complement)1,2; inhibition of parasite multiplication by
soluble factors released by monocytes in response to merozoite
binding by antibody, so-called antibody-dependent cellular inhi-
bition (ADCI)3; neutrophil antibody-dependent respiratory burst
activity upon encounter with opsonized merozoites4; merozoite
phagocytosis by monocytes or neutrophils5,6; multiple effects of
antibody binding to the infected erythrocyte surface7; and inhi-
bition of blood-stage parasites by mechanisms orchestrated by
CD4+ or CD8+ T cells8,9. Analysis of associations between
activity measured in these assays and naturally acquired clinical
immunity are complicated by the extent of exposure to malaria.
Seminal passive transfer experiments in humans involved the
transfer of total human IgG with multiple specificities and mul-
tiple potential effector mechanisms10,11.
The best-standardized and most widely used tool for assess-
ment of blood-stage vaccine-induced antibody functionality is the
assay of growth inhibitory activity (GIA). This measures
antibody-mediated P. falciparum merozoite neutralization in
erythrocyte cultures lacking any FcR-bearing cells and without
addition of complement1. Notably, the relationship between GIA
and naturally acquired malaria immunity is contentious12, with
the latter very likely due to a complex interplay of multiple
immune responses. In contrast, an association between GIA and
vaccine-induced protection has been observed in four non-
human primate (NHP) vaccination studies13–16. Presence of
additional unmeasured vaccine-induced causes of protection
could not be excluded in these studies.
In order to resolve this uncertainty and to provide the field
with clarity regarding appropriate means of selecting improved
anti-merozoite vaccines, we wished to test the existence of a
causal relationship between GIA-inducing antibody and protec-
tion against P. falciparum. We therefore set out to perform a
passive transfer study in Aotus nancymaae, i.e., intact immuno-
competent NHP which are highly susceptible to the P. falciparum
blood-stage parasite. We demonstrate that high levels of neu-
tralizing antibodies can achieve protection. This demonstration of
a causal relationship between a defined immunological mechan-
ism and protection may enable the use of GIA as a mechanistic
correlate of protection17 after vaccination of humans, facilitating
future vaccine development.
Results
Properties of chimeric anti-PfRH5 mAbs. We previously
reported the isolation of a panel of murine mAbs against
PfRH518. 2AC7 is the most potent merozoite-neutralizing anti-
PfRH5 mAb of which we are aware: it recognizes a conforma-
tional epitope which has not been accurately mapped but, on the
basis of competition binding experiments, is thought to be similar
to that of 9AD4 (another mAb) at the apex of PfRH5’s kite-like
structure18,19. 4BA7 is a non-neutralizing anti-PfRH5 mAb which
binds a linear epitope in a disordered loop remote from the
9AD4 and basigin binding sites18,19. To achieve sufficient in vivo
half-life of these two mAbs for an NHP passive transfer study,
we developed mouse-human IgG1 chimeric 2AC7 (c2AC7), and
chimeric 4BA7 (c4BA7). To exclude the possibility of Fc-
mediated antibody effector functions, the Fc region used was a
previously reported version (hIgG1Δnab) with mutations in
regions critical for binding to the activating human FcRs (FcγRIa,
FcγRIIa and FcγRIIIa) and complement component C1q20.
This mutant Fc region fails to activate monocytes, human natural
killer cell-mediated antibody-dependent cellular cytotoxicity, or
cell lysis via the classical complement pathway20 (and personal
communication from M. Clark and K. Armour). As a control, we
produced versions of an irrelevant human mAb, EBL040 (direc-
ted against the Ebola virus glycoprotein) with two Fc regions,
both hIgG1Δnab and wild-type hIgG1. All mAbs referred to in
this report carried the hIgG1Δnab except where use of EBL040
with the wild-type hIgG1 Fc is explicitly stated.
To assess their suitability for use in our planned study (and
particularly in view of the fact that there is, to our knowledge, no
prior data regarding use of human mAbs in Aotus spp.), we
characterized the resulting mAbs in vitro and in vivo. c2AC7 and
c4BA7 behaved similarly to their parental murine mAbs in
the assay of GIA, with an EC50 of 12 µg/mL for c2AC7 (Fig. 1a).
The hIgG1Δnab Fc region abrogated interaction of mAbs with
A. nancymaae C1q (as assessed by ELISA, Fig. 1b) and FcγRIa,
FcγRIIa and FcγRIIIa (as assessed by surface plasmon resonance
[SPR], Fig. 1c, d). In a pilot pharmacokinetic study, in vivo half-
life of the c4BA7 mAb plasma concentration was 7 days (Fig. 1e).
Protection against P. falciparum by neutralizing PfRH5 mAb.
We proceeded to perform two studies in which Aotus received a
challenge with 10,000 P. falciparum FVO-strain blood-stage
parasites, followed by doses of mAb. Initial doses were adminis-
tered immediately after challenge; quantities of these initial doses
are those referred to subsequently as the dose level for each group.
Informed by the pharmacokinetic data, “top-ups” of half the
original dose were given at days 7 and 14 to maintain steady
plasma concentrations. We initially tested a high dose of
100 mg/kg, with the aim of providing a definitive answer about
mAb-mediated protection. At this dose, the GIA-inducing mAb
c2AC7 was highly effective in suppressing parasitemia whereas
the non-GIA-inducing anti-PfRH5 c4BA7 mAb had no effect,
similar to the irrelevant EBL040 mAb (Fig. 2a–c). As previously
used, the protocol-specified primary endpoint for efficacy ana-
lyses was log10-transformed cumulative parasitemia up to the day
on which the first animal within the study reached a treatment
endpoint (Fig. 2d; henceforth “LCP”)14,21. At day 10, when the
first animals in the EBL040 and c4BA7 groups required treat-
ment, parasitemia was not microscopically detectable in animals
receiving 100 mg/kg c2AC7 (P < 0.0001 for reduction in LCP
by c2AC7 as compared to EBL040 by the protocol-specified
one-tailed unpaired t-test with Welch’s correction for unequal
variance; P= 0.002 by two-tailed Mann–Whitney test; P > 0.2 for
difference between LCP in c4BA7 and EBL040 recipients by
either analysis). Late in the challenge, from day 29 onward, low-
level parasitemia was detected microscopically in some c2AC7-
recipient animals: repeatedly in 2/6 animals and on a single
occasion in a further 2/6 animals, while the remaining 2/6 ani-
mals were microscopically negative throughout (Fig. 2c). At the
end of the challenge period (using larger blood samples which
could only be obtained on a single occasion), parasitemia was
detected in 3/6 animals using a sensitive quantitative polymerase
chain reaction (qPCR) assay with a lower limit of detection of
approximately 20 parasites/mL of blood22; the remaining 3/6
animals were qPCR negative (Fig. 2e).
Relationship between mAb concentration and protection. In a
separate challenge study, we assessed the effect of lower doses of
c2AC7 (Fig. 2f–h). Protection was not analyzed statistically in
view of the small number of animals at each dose level (n= 2).
Although there was a trend towards delayed treatment in some
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animals receiving c2AC7 at doses from 8 to 33 mg/kg, all animals
developed sustained parasitemia and ultimately required treat-
ment. Despite the need to exercise care in comparing between
separately performed challenge studies, the outcomes in these
animals were clearly different to outcomes at the 100 mg/kg dose
level (Fig. 2c vs. h).
To further explore the relationship between anti-PfRH5
antibody concentration, parasite neutralization and protection
against P. falciparum, we performed ELISA and GIA assays.
ELISA-measured plasma concentrations of mAbs in the high-
dose study are shown in Fig. 3a. The geometric mean c2AC7
concentration in animals receiving 100mg/kg was 728 µg/mL
(range: 626–914 µg/mL) at day 3, and similar concentrations were
maintained until around day 21 (due to the use of top-up doses).
As expected, plasma concentrations of mAbs in the low-dose
study were proportionately lower (Fig. 3b). To assess relation-
ships between mAb concentration and outcome, we calculated
time-weighted mean [TWM] mAb concentrations for each
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Fig. 1 Chimeric mAbs have desired properties for a challenge study. Panel a shows GIA with murine (dashed lines) and chimeric (solid lines) versions of
2AC7 (red lines) and 4BA7 (black lines) against FVO-strain parasites. Error bars indicate range of two independent experiments (with each experiment’s
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animal for the period days 0–14 (providing a single representative
concentration measure, despite the fluctuation in mAb concen-
trations over time due to top-up dosing). There was a relationship
between TWM c2AC7 concentration and challenge outcome
(Fig. 3c). The lowest TWM c2AC7 concentration in a 100mg/kg
c2AC7 recipient was 614 µg/mL; this animal had no detectable
parasitemia at any point in the study by microscopy or qPCR.
Time-weighted mean c2AC7 concentrations were as high as
185 µg/mL in the low-dose study in which all animals required
treatment.
Consistent with the measured pharmacokinetics, antibody
concentrations fell fairly rapidly after the final dose (Fig. 3a, b, d).
By day 35, c2AC7 concentrations in some 100mg/kg recipients
were in the same range as peak concentrations in the (non-
protected) 33 mg/kg recipients: the two 100mg/kg recipients with
repeated microscopically detectable parasitemia after day 28 were
those with the lowest c2AC7 concentration by day 35 (111 and
156 µg/mL; Fig. 3d). Thus although peak concentrations in the
100 mg/kg recipients were protective against emergence of patent
parasitemia, subpatent parasitemia must have persisted; the
artificially rapid late decline in antibody concentrations (faster
than would be expected after vaccination or hIgG1 administration
to humans23) unmasked such persistent parasites. Further
extension of the study, with the frequent blood sampling
necessary to assure prompt treatment if indicated, was not
permitted for animal welfare reasons.
We previously reported a quantitative relationship between
PfRH5 vaccine efficacy in Aotus and antibody activity in the assay
of GIA14. We introduced the measure of “GIA50 titer”, calculated
by dividing the plasma total IgG concentration by the total IgG
GIA EC5014—thus giving the plasma dilution factor required to
achieve 50% GIA in the assay. We found that animals were
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protected against a similar P. falciparum challenge if the GIA50
titer exceeded 5; animals with GIA50 titers as high as 3.5 were
not protected. The comparison included animals receiving
quite different PfRH5-based vaccines and additional unmeasured
effectors could not be excluded. Here, because of ethical
restrictions on blood sampling during the challenge resulting in
small sample volumes, GIA was assessed using IgG purified from
day 10 samples pooled from 2 monkeys within a single treatment
group (Fig. 3e). The median GIA EC50 for 100 mg/kg c2AC7
recipients was 0.16 mg/mL total IgG (range: 0.12–0.22 mg/mL);
the GIA EC50 for 33 mg/kg c2AC7 recipients was 0.61 mg/mL.
GIA50 titers in the protected pairs of 100 mg/kg c2AC7 recipients
ranged from 14 to 20; the GIA50 titer for the non-protected
pair of 33 mg/kg c2AC7 recipients was 4. The similarity of these
results to those in our earlier vaccination study is consistent with
the hypothesis that merozoite-neutralizing antibody, as measured
by GIA, is the principal cause of protection in both contexts.
Discussion
To our knowledge, this is the first example of protection of pri-
mates against P. falciparum, the principal cause of human malaria
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mortality, by transfer of a mAb: indeed, as far as we are aware,
no single immune effector—of known specificity, in the absence
of others—has previously been shown to protect either humans or
primates against P. falciparum.
We recently reported protection by an anti-PfRH5 mAb in an
immunodeficient humanized mouse model engrafted with human
hepatocytes and erythrocytes, but the dose–response relationship
between mAb concentration, GIA and protection was not stu-
died24. Moreover, the mice were receiving ongoing immuno-
suppressive drug treatment, had only 20–30% human (and hence
P. falciparum susceptible) erythrocytes at the onset of blood-stage
infection, and had microscopically detectable circulating schi-
zonts (suggesting that the model does not fully recapitulate the
cytoadherence of late-stage parasites which is a critical feature of
P. falciparum pathogenesis). Our present study complements and
extends that finding in an intact immunocompetent NHP model
known to support P. falciparum sequestration25,26.
Protection was achieved here by a mAb with a mutant Fc
designed to be incapable of engaging FcR or complement-
mediated effector functions. The presence of an Fc region con-
tributes to merozoite neutralization by 2AC7 and other anti-
PfRH5 antibodies, perhaps via bivalent binding or steric effects,
but independent of FcR18. Importantly, the objective of this study
was to validate the possibility of protection by an FcR-
independent mechanism (and hence the use of the GIA assay
as a surrogate of protection): not to formally exclude the possi-
bility of FcR-dependent augmentation of protection by anti-RH5,
and certainly not to exclude the possibility of FcR-dependent
protection by antibodies of other specificities. PfRH5’s prior-
itization as a vaccine antigen (and the isolation of the 2AC7 mAb)
has been on the basis of the GIA assay and its essential interaction
with the receptor basigin (suggesting the possibility of invasion
inhibition by FcR-independent steric blockade)18,27,28. To our
knowledge, PfRH5 has never been shown to be a target of FcR-
dependent anti-merozoite effects and we are doubtful that it is an
appropriate target. Rather, the principal targets of antibodies
acting via such mechanisms appear to be abundant merozoite
surface proteins2,29,30—perhaps a necessity for recruitment of
these functions—while PfRH5 is neither abundant nor easily
accessible on the merozoite surface until late in invasion18,31.
There remains, in our opinion, a need for validation of the
in vivo protective effects against malaria of complement- and FcR-
dependent antibody effector mechanisms. Candidate mAbs selected
specifically for their potency in in vitro assays of these activities
(most likely binding to non-PfRH5 antigens, and ideally without
potent neutralizing activity) could readily be tested for their in vivo
protective capacity, comparing versions with wild-type Fc and with
mutant Fc regions such as hIgG1∆nab. Such direct evidence is likely
to provide stronger support for vaccine development than can be
obtained from epidemiological studies, in which the multifactorial
nature of natural immunity makes it impossible to isolate the causal
contribution to protection of a single mechanism.
Levels of anti-PfRH5 antibody and GIA required to suppress
parasite multiplication were high, despite the in vitro potency of
c2AC7 (we are not aware of any mAb which is substantially more
potent in the assay of GIA, either from our own work or that of
others). Anti-PfRH5 concentrations necessary to achieve protec-
tion were orders of magnitude higher than those commonly seen
in individuals from malaria-endemic regions: in a previous study
testing sera from 175 Kenyan and Ghanaian adults, we found
median anti-PfRH5 responses of <0.1 µg/mL and a maximum
response of 3 µg/mL32. We therefore doubt that naturally-
acquired anti-PfRH5 responses are major contributors to nat-
ural immunity.
Achievement of a given reduction in parasite multiplication
in vivo (whether after vaccination14 or here after passive transfer),
appears to require neutralizing antibody concentrations which are
multiples of those needed to achieve similar effects in vitro. This
is consistent with other pathogens, such as smallpox and polio,
for which neutralization assays are accepted surrogates of pro-
tection33. The precise quantitative relationship between anti-
PfRH5 antibody concentration, GIA and protection is likely to
differ between malaria-naïve Aotus and humans living in malaria-
endemic areas: current and future clinical trials will assess this
relationship in humans, and the possibility of synergy between
vaccine-induced anti-PfRH5 responses and naturally-acquired
responses to other parasite antigens. Notwithstanding these
possibilities, the attainment and maintenance in humans of the
levels of antibody required to achieve protection in this study
would be extremely challenging with currently available vaccine
platforms.
Our data thus invite two interpretations. On a positive note, in
a field which has struggled to understand the mechanisms of
vaccine-induced protection, this is perhaps one of the clearest
dissections of the quantitative relationship between any candidate
P. falciparum vaccine effector, an in vitro assay, and in vivo
protection. On the other hand, although merozoite-neutralizing
antibody can in principle be protective, there is a substantial
quantitative hurdle to be overcome in order to develop a clinically
useful vaccine acting by this mechanism. This clarity is likely
to be instructive for future vaccine candidate selection: the level
of GIA induced by anti-PfRH5 antibodies should serve as a
benchmark to be exceeded by future vaccines aiming to protect by
merozoite neutralization, and the validation of additional possible
mechanisms of protection should be a priority.
Methods
Monoclonal antibody production. We previously described production of 2AC7
and 4BA7 anti-PfRH5 murine hybridomas18. mRNA isolated from the hybridomas
was used as a template to RT-PCR amplify the respective antibody rearranged
variable heavy and light chains34. Heavy- and light-chain variable region coding
sequences were then gene synthesized (Thermo Fisher) and subcloned into
transient mammalian expression vectors in frame with the hIgG1Δnab20 or hIgCκ
chain constant sequences as appropriate.
Isolation of the plasmids encoding the light and heavy chains of the human
IgG1 monoclonal EBL040, directed against Ebola virus glycoprotein, has been
reported elsewhere35. The EBL040 VH and VL sequences were subcloned using
InFusion (Clontech) into mammalian expression vectors in frame with
hIgG1Δnab20, wild-type hIgG1 (to produce the EBL040 with wild-type hIgG1,
used only in Fig. 1b–d) or hIgCκ chain constant sequences.
Monoclonal antibody (mAb) was produced by transient transfection of
plasmids into HEK293F cells in Expi293 media (Thermo Fisher) using 25 kDa
linear polyethylene-imine (PEI, Polysciences). mAb was purified on a protein G
column, with a 0.5 M arginine wash step for endotoxin reduction, followed by a
size-exclusion chromatography (SEC) step to remove aggregates and further reduce
endotoxin, and concentration adjustment/buffer exchange using a centrifugal filter
device (Vivaspin, Sartorius). SEC chromatograms confirmed >99.5% purity (in that
>99.5% of the mAb preps were of the expected molecular weight). Endotoxin
levels were <0.5 EU/mg (LAL Chromogenic Assay Kit, Thermo Fisher).
Binding of mAbs to Aotus nancymaae C1q and Fcγ receptors. C1q binding was
assessed by ELISA. Maxisorp plates (ThermoFisher) were coated overnight with
EBL040-hIgG1, EBL040-hIgG1∆nab, or c2AC7 mAbs (50 µL at 5 µg/mL in
phosphate-buffered saline [PBS]), and blocked for 1 h with Blocker Casein
(ThermoFisher). A dilution series of pooled plasma from mAb-naïve A. nancymaae
(5-fold from a 1:20 starting dilution) was applied for 2 h, followed by application
of horseradish-peroxidase-conjugated sheep anti-human C1q polyclonal antibody
(Abcam ab46191, diluted 1:100 in Blocker Casein) for 1 h. Plates were developed
with TMB substrate (ThermoFisher) for 1 h and absorbance was measured at
650 nm on a Clariostar reader (BMG).
FcγRIa, FcγRIIa, and FcγRIIIa were selected for study from the set of Fcγ
receptors on the basis that these are the major ‘activating’ effector-function mediating
Fcγ receptors in humans36. Predicted mRNA sequences encoding A. nancymaae
homologs of these human receptors were identified by searching NCBI data arising
from the Owl Monkey Genome Project (Baylor College of Medicine Human Genome
Sequencing Centre; https://www.hgsc.bcm.edu/non-human-primates/owl-monkey-
genome-project). Sequences retrieved (NCBI accession numbers XM_012442107.1,
XM_012449596.1, XM_012449592 and the corresponding predicted protein
sequences XP_012297530.1, XP_012305019.1 and XP_012305015.1) were BLAST
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aligned against human receptor reference sequences (Uniprot P12314, P12318,
P08637). Probable Aotus receptor ectodomain sequences were inferred from the
alignments, corresponding to amino acids 54–345 of XP_012297530.1 for Aotus
FcγRIa, amino acids 1–216 of XP_012305019.1 for FcγRIIa, and amino acids 103–310
of XP_012305015.1 for FcγRIIIa. In the cases of FcγRIa and FcγRIIIa, the first
amino acids of the selected regions aligned with the human orthologs, while the
predicted N-terminal portions of the Aotus protein sequences did not align with the
N-terminus of the human orthologs and are likely to have represented erroneous
bioinformatics predictions. The coding sequences for the predicted Aotus receptor
ectodomains were synthesized with flanking NotI and AscI restriction enzyme sites
(Thermo Fisher), and subcloned into a previously reported pTT3-based vector
supplying C-terminal tag sequences (rat CD4 domains 3 and 4, biotin acceptor
peptide, and hexa-histidine (6xHis))37. Biotinylated receptor protein was produced
by transient co-transfection of HEK293F cells with these plasmids and a plasmid
encoding the BirA biotin ligase37. Harvested cell supernatant was dialyzed extensively
against PBS.
Surface plasmon resonance was performed using a Biacore X100 instrument
and biotin-CAP chip (both from GE Healthcare), at an analysis temperature of
25 °C and a flow rate of 30 µL/min. Running buffer comprised HEPES-buffered
saline, pH 7.4, supplemented with 3 mM EDTA, 0.05% Tween-20, 1 mg/mL
salmon DNA and 2 mg/mL carboxymethyl-dextran (all from Sigma) HBS-EP+
running buffer38. At least 2500 response units (RU) of biotinylated FcγR protein
was captured on flow cell 2 (Fc2). Fc1 received CAP reagent alone.
Analyte test samples comprised two positive controls for binding (protein
G-purified polyclonal Aotus IgG and EBL040 mAb with wild-type human IgG1 Fc,
EBL040-hIgG1); two mAbs with the mutant hIgG1Δnab Fc (EBL040-hIgG1Δnab
and c2AC7), and blank (buffer only). All antibodies were tested at 100 µg/mL.
Analytes were injected over the both flow cells for 60 s. Peak background
subtracted binding (i.e., Fc2-1) was calculated.
Animals and veterinary procedures. The experiments reported herein were
conducted in compliance with the Animal Welfare Act and in accordance with the
principles set forth in ref. 39. The study protocol was approved by NAMRU-6’s
Institutional Animal Care and Use Committee (protocol number NAMRU-6
14-06); the Department of the Navy Bureau of Medicine and Surgery (NRD-927);
the University of Oxford’s central committee on Animal Care and Ethical Review
(ACER); and the Institut Nacional de Recursos Naturales (INRENA) at the
Peruvian Ministry of Agriculture.
Adult female owl monkeys (A. nancymaae) were housed at the US Naval Medical
Research Unit No. 6 (NAMRU-6), Lima, Peru. Intravenous (i.v.) administration of
antibodies and parasites and withdrawal of blood samples from the saphenous vein
was performed under ketamine anesthesia. EDTA-anticoagulated blood was prepared
using standard methods to obtain plasma and in some cases PBMC.
In a preliminary study to assess mAb pharmacokinetics, n= 2 Aotus were
administered a 30mg/kg i.v. bolus of chimerized anti-PfRH5 mAb c4BA7. Plasma
samples were collected at intervals up to day 22; mAb concentrations measured
by ELISA (see below); and a single-phase exponential decay model was fitted to
data collected from day 3 onward to estimate terminal elimination half-life. On day 7
of this preliminary study, one animal additionally received an anti-CD20 mAb
(Arzerra, GSK), as part of a concurrent study to be published separately; exclusion
of data collected after that administration altered the point estimate of the fitted half-
life by less than 1 day.
For challenge studies, randomization to groups was stratified by prestudy
weight and gender. Animals were challenged i.v. on day 0. Challenge inocula
comprised 104 FVO-strain P. falciparum iRBC taken from a donor monkey40.
Immediately after administration of the challenge inoculum and a PBS flush, the
appropriate dose of mAb was administered i.v. in 2 mL of PBS. Additional doses
of mAb, each half the initial dose given to that animal, were administered on days 7
and 14. Antibodies and doses were as set out in figure legends; passively transferred
EBL040 mAb also had the hIgG1Δnab Fc.
From day 3, daily thin-film parasitemia quantification and alternate-day Hct
measurements were conducted. Animals were treated when (i) parasite density
reached ≥200,000/μL; or (ii) Hct fell to ≤25% (severe anemia is a common
complication of poorly controlled malaria infection in Aotus); or (iii) upon
reaching challenge day 35 if no other treatment endpoint had been reached.
P. falciparum quantitative PCR was performed using a TaqMan-based assay22,
modified in that test samples comprised 200 µL of packed Aotus RBCs, filtered
through CF11 cellulose powder to remove leukocytes41.
ELISA and GIA. c2AC7, c4BA7, EBL040, and total Aotus IgG in plasma samples
were quantified by ELISA.
In the case of c2AC7 and c4BA7, streptavidin-coated plates (ThermoFisher)
were coated with saturating quantities of monobiotinylated PfRH5 protein
produced by transient transfection of HEK293E cells (Canadian National Research
Council)14,27. For EBL040, plates were coated with 100 ng per well of trimeric
Ebola virus Zaire glycoprotein (aa 1–650) with a four amino acid C-terminal C-tag
(EPEA)42, produced by transient transfection of HEK293 cells14, supernatant
concentration by tangential flow filtration with 10 kDa membrane cut-off
(Millipore), CaptureSelect C-tag affinity chromatography (Thermo Fisher
Scientific) using 2M MgCl2, 20 mM Tris pH 7.4 elution buffer, and finally
SEC in Tris-buffered saline using a HiLoad Superdex16/600 200 pg column
(GE Healthcare). All three antibodies were detected using alkaline-phosphatase-
conjugated goat anti-human IgG (Sigma A3187, 1:1000 dilution).
For measurement of day 0 Aotus IgG (prior to mAb administration), a self-
sandwich design was used: Maxisorp plates (ThermoFisher) were coated with
rabbit anti-monkey IgG polyclonal antibody (Sigma A2054, 1:1000 dilution); the
secondary antibody was an alkaline-phosphatase-conjugated version of the same
antibody (Sigma A1929, 1:1000 dilution).
Plates were developed with para-nitrophenyl-phosphate substrate (Sigma) in
diethanolamine buffer (ThermoFisher) and read using an ELx800 instrument (Biotek).
Conversion to plasma concentration was made by comparison of OD readings to a
dilution series of the appropriate mAb or protein G-purified Aotus IgG43.
For Fig. 3c, time-weighted mean (TWM) mAb concentrations were calculated
from the ELISA data by using the trapezoidal rule to find area under the curve
between each assay timepoint and dividing by the time intervals; in the absence of
measured peak (day 0) levels, a constant rate of decay from day 0 through the
measured values at days 3 and 7 was assumed.
Assays of GIA were performed using the FVO parasite line1. Assays using purified
mAb to assess function after chimerization (results in Fig. 1a) were performed in the
Jenner Institute Laboratory. Assays using Aotus samples (results in Fig. 3e) were
performed at the GIA Reference Center Laboratory, NIAID, NIH. IgG was purified
from pooled plasma samples of 100 µL from each of a pair of monkeys (within the
same mAb treatment group), collected on day 10 after challenge. Both laboratories
used the GIA Reference Centre’s method, involving single-cycle parasite growth and
colorimetric detection of parasite lactate dehydrogenase1.
GIA EC50 was estimated by linear interpolation. GIA50 titer was calculated by
dividing the day 0 plasma total IgG concentration by the total IgG GIA EC50.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data analysis and availability of data and reagents
All analyses were performed using Prism software (GraphPad). All relevant data is
presented within the manuscript in graphical form. Raw numerical data and reagents are
available from the authors on reasonable request.
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